Terminal nucleotidyltransferase 4B (TENT4B; PAPD5) inhibitors have been described in a Childrens Medical Center Corp. patent. As such, they are reported to be useful for the treatment of cancer, osteoarthritis, macular degeneration, hepatitis B, pulmonary fibrosis, diabetes, pontocerebellar hypoplasia and cardiovascular disorders, among others.
The University of Oxford and Selvita SA have established an integrated drug discovery collaboration in the area of Parkinson’s disease. Based on evidence implicating α-synuclein aggregates as the cause of Parkinson’s, the approach looks at the inability of cells to efficiently clear these aggregates, which may lead to the death of neurons and the emergence of characteristic symptoms of the disease. Promoting the ability of nerve cells to rid themselves of these aggregates therefore offers a possible therapeutic strategy for Parkinson’s disease.
Researchers from Xinhua Hospital have published data from a study that aimed to assess the role of CEBPG, an important regulator of tumor development, in the progression of ovarian cancer (OC).
Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
RSS
